Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Eluxadoline

(Viberzi®)

Viberzi®

Drug updated on 9/4/2024

Dosage FormTablet (oral; 75 mg, 100 mg)
Drug Classmu-opioid receptor agonist
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Viberzi (eluxadoline) is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • IBS Global Symptoms and Bowel Movement Frequency: A meta-analysis of 9 studies involving 4,156 patients showed that opioid receptor modulators, including eluxadoline, significantly improved IBS global symptoms (RR = 0.85, 95% CI = 0.79-0.92, P < 0.01) and reduced bowel movement frequency (SMD = -1.26, 95% CI = -2.49--0.04, P < 0.05). Improvements in stool consistency and quality of life were not statistically significant.
  • Overall Response to Therapy in IBS-D or IBS-M: A network meta-analysis of 18 RCTs with 9,844 patients found all drugs, including eluxadoline, were superior to placebo at 12 weeks based on the FDA-recommended endpoint. Alosetron 1 mg twice daily was ranked highest for efficacy, followed by ramosetron and then eluxadoline.
  • Comparison to Other Drugs: Alosetron 1 mg twice daily ranked first for efficacy based on the FDA-recommended composite endpoint, ramosetron 2.5 µg once daily ranked highest for abdominal pain relief, and rifaximin 550 mg three times daily was ranked first for safety, though it was less effective than alosetron and ramosetron.
  • In IBS-C and IBS-D trials, active drugs were associated with higher rates of adverse events compared to placebo. Diarrhea and headache were more common in IBS-C trials, and constipation, nausea, and abdominal pain were more common in IBS-D trials.
  • Rifaximin 550 mg three times daily was ranked highest for safety, with fewer adverse events compared to other drugs, while alosetron and ramosetron had significantly more adverse events compared to placebo.
  • Significant adverse events were observed in both IBS-C (diarrhea, headache) and IBS-D (constipation, nausea, abdominal pain) trials when treated with active drugs, including eluxadoline and other opioid receptor modulators.